Literature DB >> 30631206

CAR T cell therapy: inroads to response and resistance.

Christine E Brown1, Crystal L Mackall2.   

Abstract

Year:  2019        PMID： 30631206     DOI： 10.1038/s41577-018-0119-y

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


× No keyword cloud information.
  66 in total

Review 1.  How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.

Authors:  Jinyang Li; Ben Z Stanger
Journal:  Cancer Res       Date:  2020-06-18       Impact factor: 12.701

Review 2.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

3.  Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer.

Authors:  Cassandra E Callmann; Lisa E Cole; Caroline D Kusmierz; Ziyin Huang; Dai Horiuchi; Chad A Mirkin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

Review 4.  Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.

Authors:  Dana L Casey; Nai-Kong V Cheung
Journal:  Cancer Immunol Res       Date:  2020-02       Impact factor: 11.151

5.  PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.

Authors:  Katherine D Gray; Jaclyn E McCloskey; Yogindra Vedvyas; Olivia R Kalloo; Steve El Eshaky; Yanping Yang; Enda Shevlin; Marjan Zaman; Timothy M Ullmann; Heng Liang; Dessislava Stefanova; Paul J Christos; Theresa Scognamiglio; Andrew B Tassler; Rasa Zarnegar; Thomas J Fahey; Moonsoo M Jin; Irene M Min
Journal:  Clin Cancer Res       Date:  2020-09-04       Impact factor: 12.531

6.  Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic.

Authors:  Laura T Morton; Rogier M Reijmers; Anne K Wouters; Christiaan Kweekel; Dennis F G Remst; Cilia R Pothast; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Mol Ther       Date:  2019-10-04       Impact factor: 11.454

Review 7.  Computational approaches for characterizing the tumor immune microenvironment.

Authors:  Candace C Liu; Chloé B Steen; Aaron M Newman
Journal:  Immunology       Date:  2019-10       Impact factor: 7.397

Review 8.  Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Authors:  Ryan D Salinas; Joseph S Durgin; Donald M O'Rourke
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

Review 9.  Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Authors:  Anupama Doraiswamy; Mansi R Shah; Rajat Bannerji
Journal:  Curr Hematol Malig Rep       Date:  2021-02-22       Impact factor: 3.952

10.  Tuning the Antigen Density Requirement for CAR T-cell Activity.

Authors:  Robbie G Majzner; Skyler P Rietberg; Elena Sotillo; Rui Dong; Vipul T Vachharajani; Louai Labanieh; June H Myklebust; Meena Kadapakkam; Evan W Weber; Aidan M Tousley; Rebecca M Richards; Sabine Heitzeneder; Sang M Nguyen; Volker Wiebking; Johanna Theruvath; Rachel C Lynn; Peng Xu; Alexander R Dunn; Ronald D Vale; Crystal L Mackall
Journal:  Cancer Discov       Date:  2020-03-19       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.